ロード中...
Disposition of Erlotinib and Its Metabolite OSI420 in a Patient with High Bilirubin Levels
Erlotinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for the treatment of non-small cell lung cancer and when combined with gemcitabine for pancreatic cancer. Dose reduction of erlotinib in patients with severe hepatic impairment has been established. We pr...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
S. Karger AG
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3901587/ https://ncbi.nlm.nih.gov/pubmed/24474924 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000357211 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|